ArticleJournal of pharmaceutical policy and practice2026
Rarely listed essential medicines in 158 national lists.
Article in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Health needs are relatively similar across the planet as there are few conditions that are truly unique to one region or country, and most conditions are common around the world. Differences in health needs do not explain differences in national essential medicines lists. Factors other than health needs may well lead different countries to select different medicines. The purpose of this study is to identify and describe medicines listed by only a small number of countries. Methods: Using the Global Essential Medicines database of NEMLs that was updated in 2023 and 2025, we identified medicines listed by 2 or fewer countries that were not listed on the 2023 World Health Organization's Model List of Essential Medicines. We characterized these rare medicines and their indications based on information obtained from the NEMLs that listed them, and also performed literature searches for each rarely listed medicine. We also identified which countries listed many rare medicines (5 or more) and performed literature searches to explore possible explanations for them being rarely listed. Results: We identified 460 rarely listed essential medicines, including 317 medicines that were listed in the NEML of only one country, and 143 medicines that were listed by two countries. A total of 83 countries listed at least one rare medicine, including 30 countries that listed many (5 or more) rarely listed medicines and 53 that listed few rare medicines. Countries that listed many rare medicines included Greece, Australia, and the Russian Federation. Conclusion: Certain medicines are prioritized for access in just one or two countries, and some countries list many such medicines. Further work is needed to understand why certain medicines are rarely listed and whether changes to lists are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.